Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8TCQ1

UPID:
MARH1_HUMAN

ALTERNATIVE NAMES:
Membrane-associated RING finger protein 1; Membrane-associated RING-CH protein I; RING finger protein 171; RING-type E3 ubiquitin transferase MARCHF1

ALTERNATIVE UPACC:
Q8TCQ1; D3DP29; Q9NWR0

BACKGROUND:
The protein E3 ubiquitin-protein ligase MARCHF1, with alternative names such as RING finger protein 171, orchestrates the ubiquitination and subsequent lysosomal degradation of proteins critical for immune response. By controlling the cell surface localization of MHC class II proteins in dendritic cells, it plays a key role in immune tolerance and activation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of E3 ubiquitin-protein ligase MARCHF1 offers a promising pathway for the development of novel immunotherapies. Its central role in managing immune responses provides a unique opportunity for therapeutic intervention in diseases where immune regulation is compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.